Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Dechra Pharmaceuticals's Enterprise Value is £4,831.4 Mil.
Dechra Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £7.8 Mil. Therefore, Dechra Pharmaceuticals's EV-to-EBIT ratio for today is 619.41.
Dechra Pharmaceuticals Enterprise Value Historical Data
The historical data trend for Dechra Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dechra Pharmaceuticals's Enterprise Value
For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dechra Pharmaceuticals's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Dechra Pharmaceuticals's Enterprise Value falls into.
Dechra Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Dechra Pharmaceuticals's Enterprise Value for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dechra Pharmaceuticals (LSE:DPH) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Dechra Pharmaceuticals's current Enterprise Value is £4,831.4 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Dechra Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £7.8 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Dechra Pharmaceuticals's EV-to-EBITDA for today is:
Dechra Pharmaceuticals's current Enterprise Value is £4,831.4 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Dechra Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was £97.5 Mil.
Dechra Pharmaceuticals's current Enterprise Value is £4,831.4 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Dechra Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was £761.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dechra Pharmaceuticals Enterprise Value Related Terms
Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Dechra Pharmaceuticals (LSE:DPH) Business Description
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:DPH has been successfully added to your 